Timothy M. Cunniff, PharmD

EVP, Research & Development
Paragon Biosciences, LLC

Poster(s):

• (62) Efficacy and safety of ecopipam for Tourette syndrome: results from a phase 3, randomized, double-blind, placebo-controlled withdrawal trial
  Wednesday, October 29, 2025

• (358) Increased health care resource utilization in children and adolescents with Tourette syndrome treated with dopamine D2 receptor antagonists/partial agonists: an electronic health records database analysis
  Wednesday, October 29, 2025